Item Type | Name |
Concept
|
Drug Therapy, Combination
|
Concept
|
Treatment Failure
|
Concept
|
Treatment Outcome
|
Concept
|
Withholding Treatment
|
Concept
|
Molecular Targeted Therapy
|
Concept
|
Estrogen Replacement Therapy
|
Academic Article
|
Clinical trials for lupus--are we there yet?
|
Academic Article
|
Rituximab: wanted dead or alive...
|
Academic Article
|
Ending the 50-year drought of FDA drug approval for SLE.
|
Academic Article
|
Herpes zoster vaccination in SLE: a pilot study of immunogenicity.
|
Academic Article
|
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.
|
Academic Article
|
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
|
Academic Article
|
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
|
Academic Article
|
Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study.
|
Academic Article
|
Why, why, why de-lupus (does so badly in clinical trials).
|
Academic Article
|
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
|
Academic Article
|
Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials.
|
Academic Article
|
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
|
Academic Article
|
Immunologic findings precede rapid lupus flare after transient steroid therapy.
|
Academic Article
|
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach.
|
Academic Article
|
SLE clinical trials: impact of missing data on estimating treatment effects.
|
Academic Article
|
High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin.
|
Academic Article
|
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
|
Academic Article
|
Emergence of targeted immune therapies for systemic lupus.
|
Academic Article
|
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus.
|
Academic Article
|
New directions in the treatment of systemic lupus erythematosus.
|
Academic Article
|
Connective tissue diseases: What does the death of Riquent hold for the future of SLE?
|
Academic Article
|
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
|
Academic Article
|
Treatment of systemic lupus erythematosus: a 2012 update.
|
Academic Article
|
Co-stimulatory molecules as targets for treatment of lupus.
|
Academic Article
|
Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.
|
Academic Article
|
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
|
Academic Article
|
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
|
Academic Article
|
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE).
|
Academic Article
|
Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative.
|
Academic Article
|
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.
|
Academic Article
|
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
|
Academic Article
|
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
|
Academic Article
|
Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
|
Academic Article
|
Author Correction: Immunologic findings precede rapid lupus flare after transient steroid therapy.
|
Academic Article
|
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
|
Academic Article
|
Recurrent pregnancy loss with the antiphospholipid antibody: a systematic review of therapeutic trials.
|
Academic Article
|
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
|
Academic Article
|
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
|
Academic Article
|
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
|
Academic Article
|
Disease-specific patient reported outcome tools for systemic lupus erythematosus.
|
Academic Article
|
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
|
Academic Article
|
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.
|
Academic Article
|
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
|
Academic Article
|
Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus.
|
Academic Article
|
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
|
Academic Article
|
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.
|
Academic Article
|
Catastrophic antiphospholipid syndrome.
|
Academic Article
|
Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment.
|
Academic Article
|
Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis.
|
Academic Article
|
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
|
Academic Article
|
Novel evidence-based systemic lupus erythematosus responder index.
|
Academic Article
|
The genetics of systemic lupus erythematosus and implications for targeted therapy.
|
Academic Article
|
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.
|
Academic Article
|
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
|
Academic Article
|
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
|
Academic Article
|
Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.
|
Academic Article
|
Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
|
Academic Article
|
Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.
|
Academic Article
|
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
|
Academic Article
|
Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort.
|
Academic Article
|
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications.
|
Grant
|
Polymorphisms of Antiphospholipid Protein Antigens
|
Grant
|
SPORADIC MECHANISM OF THE ANTIPHOSPHOLIPID SYNDROME
|
Grant
|
SPORADIC MECHANISM OF THE ANTIPHOSPHOLIPID SYNDROME
|
Academic Article
|
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.
|
Academic Article
|
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
|
Academic Article
|
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
|
Academic Article
|
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
|
Academic Article
|
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
|